The Long Run with Luke Timmerman

The Long Run with Luke Timmerman

Podcast3 episodes summarized

MurmurCast publishes AI-generated summaries of The Long Run with Luke Timmerman’s Podcast episodes — 3 summarized so far, covering Career progression from law to biotech leadership, LB102 drug development and mechanism of action, Schizophrenia and neuropsychiatric disorder treatment, Biotech IPO during financing freeze, Clinical trial design and placebo management, Patient adherence in mental health treatment. Each summary distills the key insights, topics, and takeaways so you can decide what’s worth your time before pressing play.

Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With

1h 8mJul 14, 2026

Heather Turner, CEO of LB Pharmaceuticals, discusses her unconventional path from corporate attorney to biotech CEO, leading the development of LB102, a methylated derivative of amisulpride for treating schizophrenia and other neuropsychiatric disorders. She successfully navigated a challenging IPO during a biotech financing freeze and is now advancing the compound through late-stage clinical trials with a focus on improving patient adherence and reducing side effects.

StoryDiscussionCareer progression from law to biotech leadershipLB102 drug development and mechanism of actionSchizophrenia and neuropsychiatric disorder treatment

Ep204: Troy Wilson on Precision Cancer Drugs and Combos

1h 7mJun 30, 2026

Troy Wilson, CEO of Cura Oncology, discusses his journey from mediocre student to serial biotech entrepreneur, the development of Ziftimenib (a Menin inhibitor approved for AML), and the company's strategy of combining precision cancer drugs like farnesyl transferase inhibitors with emerging RAS inhibitors to overcome treatment resistance.

StoryInsightfulMenin inhibitor development and mechanism of actionTroy Wilson's career trajectory and entrepreneurial journeyFarnesyl transferase inhibitors and combination therapy strategies

Ep201: Jeremy Levin on Biotech in the Balance

1h 8mMay 19, 2026

Jeremy Levin, founder of Ovid Therapeutics and author of 'Biotech in the Balance,' discusses the systemic decline in public trust toward the biotechnology industry, tracing it from the Shkreli scandal through COVID-19 and into the current era of hostile policy. He argues the industry must recognize itself as strategically vital and offers ten commitments—including transparency, patient-centricity, and long-term capital formation—to rebuild its standing with the public and policymakers.

DiscussionOpinionDecline in public trust toward the biotech industryImpact of the Shkreli scandal as a missed warningCOVID-19 vaccines and the communication failure

Get AI summaries like this delivered to your inbox daily